PA-BOOMI
15.4.2024 15:01:27 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced findings from its Boomi Discovery Report, commissioned by 451 Research.1 The report, based on perspectives from 650 business and IT leaders across a broad range of industries, outlines how enterprises are using Generative AI (GenAI) to integrate systems and automate processes, and how this has helped their business operations as a result.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415795607/en/
Boomi Discovery Report Reveals More Than Half of Enterprises Invest in GenAI for Integration and Automation (Graphic: Business Wire)
Every business is grappling with growing digital fragmentation – from application sprawl and disconnect between departments, to rising costs and skills shortages. GenAI delivers the promise of more efficient and cost-effective operations and improved customer and employee experiences, but only for businesses that embrace it.
According to the Boomi Discovery Report, organizations are seeing GenAI’s immediate impact on integration. More than half of respondents (55%) said GenAI was very important for integrating data, applications, and processes. Moreover, the global drivers of AI adoption included increased productivity (which 44% of executives cited), increased sales and revenue growth (40%), and improved customer experience (39%).
However, respondents acknowledged the complexity that’s often associated with integration. Many times, integrating data and systems can bring challenges that prompt security and privacy concerns (42%), data quality and availability challenges (42%), and model training, accuracy, and reliability (31%). According to the report, 90% of respondents agree that GenAI has the potential to improve the speed and quality of the development and automation of data, application, and process integrations.
“The ability to seamlessly integrate and automate business processes has long been a top priority for many enterprises,” said Steve Lucas, CEO at Boomi. “As organizations scale and continue to navigate unforeseen business challenges, it will become more difficult to keep track of all the data, technology, and processes necessary to achieve business goals. Generative AI can be a powerful tool for today’s enterprises, streamlining valuable integration and automation practices and freeing IT teams to focus on innovation. Finding ways to leverage GenAI effectively is the next business prerogative. Boomi is not only helping get businesses ready for it, but also leading the GenAI charge in the integration and automation space."
Additional key findings from the report include:
- IT leaders have more trust in GenAI than business leaders: IT CxOs have a higher rate of trust – 82% either “completely” or “somewhat” trust the output of GenAI, versus 63% of business CxOs.
- Accuracy and consistency are major factors driving trust in GenAI: More than half of business leaders (57%) cited accuracy and quality of AI outputs as a factor in their trust of AI. Just under half (48%) cited consistency and reliability as an AI trust factor.
- Enterprise execs see tremendous value in GenAI: Leaders cited improved process accuracy and consistency (38%), cost reduction (38%), innovation and creativity (34%), streamlined operations (31%), optimized resources (28%), and enablement of competitive advantage (27%) as top potential benefits for leveraging GenAI.
- GenAI has widespread value for integrations: All respondents believe that virtually any type of integration would benefit from GenAI-assisted integration platforms.
“Integration and automation are the foundation upon which enterprises build business agility,” said Matt McLarty, CTO at Boomi. “However, integrating and automating systems isn’t always easy. This is why it pays off to have a unified approach for both. With a unified platform, powered by AI technology, enterprises can gain the advantages of comprehensive integration and automation while mitigating unwanted complexity.”
For more information on the 2024 Boomi Discovery Report, click here.
Additional Resources
- Learn more about the Boomi platform
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
Methodology
The findings presented in this report draw on a survey fielded in North America and Europe in Q4 2023. The survey targeted 650 business and IT decision-makers/influencers in companies ranging in size from under 100 to over 25,000 employees, and $2 million to over $10 billion in annual revenue. The study prioritized respondents with intimate knowledge of automation and integration technology across a broad range of diverse industries asking them about their perception of, and propensity to use, AI technologies of various types, but more specifically about their use of GenAI. The job descriptions of respondents were a mix of executives ranging from Analyst/Manager grade to C-level Executives. This report also draws on contextual knowledge of additional research conducted by S&P Global Market Intelligence.
|
|
1Source: The Impact of AI on Enterprise Integration and Automation, 451 Research, a part of S&P Global Market Intelligence and Boomi, 2024. All Rights Reserved |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415795607/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
